ERAS Quote, Financials, Valuation and Earnings

Amicus Therapeutics, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of 0.91%. Erasca, Inc.'s return on equity of -33.33% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Erasca, Inc. has a consensus price target of $18.33, signalling upside risk potential of 35.7%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 0.91%. Given that Erasca, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Erasca, Inc. is more attractive than Amicus Therapeutics, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.430, suggesting its less volatile than the S&P 500 by 56.973%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Erasca, Inc.'s net income of -$29.1M is lower than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 7.03x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Incyte Corp. has a net margin of -- compared to Erasca, Inc.'s net margin of 19.86%. Erasca, Inc.'s return on equity of -33.33% beat Incyte Corp.'s return on equity of 30.48%.

Erasca, Inc. has a consensus price target of $18.33, signalling upside risk potential of 35.7%. On the other hand Incyte Corp. has an analysts' consensus of $107.59 which suggests that it could grow by 15.69%. Given that Erasca, Inc. has higher upside potential than Incyte Corp., analysts believe Erasca, Inc. is more attractive than Incyte Corp..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.840, suggesting its less volatile than the S&P 500 by 16.012%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Incyte Corp. quarterly revenues of $1.5B. Erasca, Inc.'s net income of -$29.1M is lower than Incyte Corp.'s net income of $299.3M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 14.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 3.63x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of --. Erasca, Inc.'s return on equity of -33.33% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Erasca, Inc. has a consensus price target of $18.33, signalling upside risk potential of 35.7%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $133.70 which suggests that it could grow by 35.05%. Given that Erasca, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Erasca, Inc. is more attractive than Revolution Medicines, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.875%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Erasca, Inc.'s net income of -$29.1M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -- compared to Erasca, Inc.'s net margin of 29.52%. Erasca, Inc.'s return on equity of -33.33% beat Tango Therapeutics, Inc.'s return on equity of -50.42%.

Erasca, Inc. has a consensus price target of $18.33, signalling upside risk potential of 35.7%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $19.67 which suggests that it could grow by 9.99%. Given that Erasca, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Erasca, Inc. is more attractive than Tango Therapeutics, Inc..

Erasca, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.761, suggesting its more volatile than the S&P 500 by 76.144%.

Erasca, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Erasca, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

Erasca, Inc. quarterly revenues are --, which are smaller than Tango Therapeutics, Inc. quarterly revenues of --. Erasca, Inc.'s net income of -$29.1M is higher than Tango Therapeutics, Inc.'s net income of -$38.7M. Notably, Erasca, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Erasca, Inc. is -- versus 33.20x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.